How Commonly Are Brain Tumors Seen in Spasmus Nutans?
Discussion
Nystagmus is periodic eye movement that is involuntary where there is a slow drift of fixation. The slow drift can be followed by a fast saccade back to fixation. The pathological movement is the slow phase, but nystagmus is described by the fast phase (i.e. horizontal nystagmus, vertical nystagmus).
Spasmus nutans (SN) is a movement disorder that is rare. The classic triad includes nystagmus, head bobbing or titubation, and torticollis, with these problems being in the absence of any ophthalmological or neurological condition. Onset is in the first year of life but ranges from 6-36 months. Time to resolution ...
Source: PediatricEducation.org - April 15, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Too much screen time linked to an epidemic of myopia among young people
Myopia is not just a commonplace vision defect. It is a significant risk factor for serious eye disease. Researcher Langis Michaud explains why less screen time will curb rising rates. (Source: the Mail online | Health)
Source: the Mail online | Health - February 18, 2019 Category: Consumer Health News Source Type: news
Personality traits moderate connections from drinking attitudes to alcohol use and myopic relief, self-inflation, and excess - Lac A, Donaldson CD.
This study examined ... (Source: SafetyLit)
Source: SafetyLit - January 17, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
How too little time outside might damage our children's sight
In both the UK and the U.S., myopia rates have doubled since the Sixties and continue to rise. In Western Europe some 56 per cent of people are expected to be short-sighted by 2050. (Source: the Mail online | Health)
Source: the Mail online | Health - January 14, 2019 Category: Consumer Health News Source Type: news
SightGlass Vision launches trial for pediatric myopia-controlling eyeglasses
Opthalmalogical device maker SightGlass Vision said yesterday that it launched a pivotal clinical trial exploring the use of its novel lenses designed to reduce the rate of progression in children between six and nine years old.
The Palo Alto, Calif.-based company’s Cypress trial is a multicenter, double-blinded, randomized controlled clinical trial that aims to enroll 255 patients across 14 clinical sites in the U.S. and Canada. The primary endpoint of the trial is the progression of myopia over 36 months, the company said.
SightGlass Visions’s lenses are intended to reduce the progression of myopia, something...
Source: Mass Device - January 11, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic sightglassvision Source Type: news
Problematic alcohol use and acute intoxication predict anger-related attentional biases: a test of the alcohol myopia theory - Massa AA, Subramani OS, Eckhardt CI, Parrott DJ.
Previous research has demonstrated a significant association between alcohol and aggression. However, the precise mechanisms underlying this relationship have yet to be fully elucidated. In the present study, we examined alcohol's effects on an attentional... (Source: SafetyLit)
Source: SafetyLit - November 21, 2018 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
How China can fix its eyesight crisis
President Xi Jinping recently described myopia as an epidemic affecting China's younger generations. (Source: CNN.com - Health)
Source: CNN.com - Health - November 15, 2018 Category: Consumer Health News Source Type: news
J & J Vision inks $26m Singapore collaborative myopia research deal
Johnson & Johnson‘s (NYSE:JNJ) Vision business said this week that it inked an approximately $26.4 million collaborative research deal with The Singapore National Eye Centre and the Singapore Eye Research Institute looking to improve treatments for myopia.
The public-private strategic partnership is the first of its kind in Asia, according J&J, and will promote exploration of how myopia develops, progresses and possible interventions.
“SNEC is honored to be working with collaborators coming together to address the growing burden of myopia,” Professor Wong said. “By leveraging the diverse str...
Source: Mass Device - November 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Research & Development johnsonandjohnson Source Type: news
EMR Data Can Predict Myopia Development
FRIDAY, Nov. 9, 2018 -- Big data and machine learning approaches can improve prediction of myopia in Chinese children, according to a study published online Nov. 6 in PLOS Medicine.
Haotian Lin, M.D., Ph.D., from Sun Yat-sen University in Guangzhou,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 9, 2018 Category: Pharmaceuticals Source Type: news
Visioneering Tech touts NaturalVue contact lens pediatric myopia study
Visioneering Technologies Inc yesterday released results from a pediatric study of its NaturalView multifocal contact lens intended to treat myopia, touting
Results from the trial were presented by study lead Dr. Thomas Aller of the UC Berkeley School of Optometry at the American Academy of Optometry Conference in San Antonio this week.
In the trial, investigators examined changes in vision and eye shape in myopic children wearing the NaturalVue multifocal contacts, with 24 children completing a six-month follow up and 19 completing 12 months. The average age in the study was 10.8 years old, the Atlanta-based company said....
Source: Mass Device - November 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Visioneering Technologies Source Type: news
Study IDs Early Life Factors Predictive of Myopia
WEDNESDAY, Nov. 7, 2018 -- Early life factors associated with myopia include maternal education, fertility treatment, summer birth, and hours spent playing computer games, according to a study published online Nov. 6 in the British Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 7, 2018 Category: Pharmaceuticals Source Type: news
Children urged to play outdoors to cut risk of shortsightedness
Research reveals link between environmental factors and rising cases of myopiaChildren should be encouraged to spend time outdoors to reduce their risk of becoming shortsighted, experts have said.Shortsightedness isrising around the world, with the condition said to have reached epidemic proportions in east Asia: estimates suggest about 90% of teenagers and young adults in China have the condition.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 7, 2018 Category: Science Authors: Nicola Davis Tags: Medical research Science UK news Health Children Society World news Source Type: news
Computer games linked to greater myopia risk, study shows
Environmental factors may now outweigh genetic ones Related items fromOnMedica Myopia rises sharply due to lifestyle factors Eye problems: the eyelids Eye problems New genes found that cause myopia Myopia could be linked to longer periods spent in education (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 7, 2018 Category: UK Health Source Type: news
Smartphones, Summer Birth Could Raise Kids' Odds for Nearsightedness
TUESDAY, Nov. 6, 2018 -- Kids with summer birthdays, especially those who spend long hours playing on smartphones and tablets, might be at greater risk for vision problems, a new study suggests.
Nearsightedness, also called myopia, is on the rise... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 6, 2018 Category: General Medicine Source Type: news
Staar Surgical shares jump on Q3 Beat
Shares in Staar Surgical (NSDQ:STAA) have risen in after-hours trading today after the medical device maker beat expectations on Wall Street with its third quarter results.
The Monrovia, Calif.-based company posted profits of approximately $1.5 million, or 3¢ per share, on sales of approximately $31.8 million for the three months ended September 28, for bottom-line growth of 24.4% on sales growth of 35.3% compared with the same period during the previous year.
Adjusted to exclude one time items, earnings per share were 7¢, well ahead of the 3¢ loss-per-share expectation on Wall Street, where analysts expected to see sa...
Source: Mass Device - October 31, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat STAAR Surgical Co Source Type: news
